Evaluation of 4-aminoquinoline derivatives with an n-octylamino spacer as potential multi-targeting ligands for the treatment of Alzheimer's disease.

[1]  R. Bateman,et al.  Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study , 2022, Alzheimer's research & therapy.

[2]  L. Lannfelt,et al.  Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease , 2022, Neurotherapeutics.

[3]  Z. Kovarik,et al.  Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease , 2022, Pharmaceuticals.

[4]  T. Hrenar,et al.  Synthesis, Biological Evaluation and Machine Learning Prediction Model for Fluorinated Cinchona Alkaloid-Based Derivatives as Cholinesterase Inhibitors , 2022, Pharmaceuticals.

[5]  M. Zlatović,et al.  4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease , 2022, Pharmaceutics.

[6]  Jianghong Dong,et al.  Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress. , 2022, European journal of medicinal chemistry.

[7]  D. Muñoz-Torrero,et al.  Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis , 2022, Pharmaceuticals.

[8]  Elisabeth Mahase.  Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns , 2021, BMJ.

[9]  P. Tariot,et al.  The case for low-level BACE1 inhibition for the prevention of Alzheimer disease , 2021, Nature Reviews Neurology.

[10]  M. Tabaton,et al.  Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg? , 2021, Antioxidants.

[11]  Ling-Qiang Zhu,et al.  Ferroptosis, a Potential Therapeutic Target in Alzheimer’s Disease , 2021, Frontiers in Cell and Developmental Biology.

[12]  M. Guglielmotto,et al.  Estrogens still represent an attractive therapeutic approach for Alzheimer’s disease , 2021, Neural Regeneration Research.

[13]  Abha Sharma,et al.  Synthesis, molecular docking and spectroscopic studies of pyridoxine carbamates as metal chelator , 2021 .

[14]  S. Bydlowski,et al.  Ferroptosis Mechanisms Involved in Neurodegenerative Diseases , 2020, International journal of molecular sciences.

[15]  Wenyuan Liu,et al.  Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism , 2020, Medicinal research reviews.

[16]  G. Marucci,et al.  Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease , 2020, Neuropharmacology.

[17]  Z. Kovarik,et al.  Enantioseparation, in vitro testing, and structural characterization of triple-binding reactivators of organophosphate-inhibited cholinesterases. , 2020, The Biochemical journal.

[18]  M. Katalinić,et al.  Targeting organophosphorus compounds poisoning by novel quinuclidine-3 oximes: development of butyrylcholinesterase-based bioscavengers , 2020, Archives of Toxicology.

[19]  J. Bockaert,et al.  Donecopride, a Swiss army knife with potential against Alzheimer's disease , 2019, British journal of pharmacology.

[20]  M. Zlatović,et al.  N-benzyl derivatives of long-chained 4-Amino-7-chloro-quionolines as inhibitors of pyocyanin production in Pseudomonas aeruginosa. , 2019, ACS chemical biology.

[21]  Mukul Sharma.  Preventing Alzheimer's Disease: Some Light in the Darkness. , 2019, Journal of the American College of Cardiology.

[22]  Z. Kovarik,et al.  Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. , 2019, Chemico-biological interactions.

[23]  M. Nguyen,et al.  Metal Ions in Alzheimer's Disease: A Key Role or Not? , 2019, Accounts of chemical research.

[24]  Alzheimer's Association∗.  2019 Alzheimer's disease facts and figures , 2019, Alzheimer's & Dementia.

[25]  Piyoosh Sharma,et al.  Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies , 2019, Progress in Neurobiology.

[26]  Hui Li,et al.  The Role of NMDA Receptors in Alzheimer’s Disease , 2019, Front. Neurosci..

[27]  Z. Kovarik,et al.  Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold , 2018, PloS one.

[28]  K. Kuča,et al.  Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier. , 2018, Current Alzheimer research.

[29]  Y. Kim,et al.  Metal Ion Effects on Aβ and Tau Aggregation , 2018, International journal of molecular sciences.

[30]  F. Nachon,et al.  Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study , 2017, Molecules.

[31]  Hong Jiang,et al.  Biometal Dyshomeostasis and Toxic Metal Accumulations in the Development of Alzheimer’s Disease , 2017, Front. Mol. Neurosci..

[32]  I. Aleksić,et al.  Long-Chain 4-Aminoquinolines as Quorum Sensing Inhibitors in Serratia marcescens and Pseudomonas aeruginosa. , 2017, ACS chemical biology.

[33]  Z. Kovarik,et al.  Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity , 2017, Journal of enzyme inhibition and medicinal chemistry.

[34]  C. H. T. de Paula da Silva,et al.  Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. , 2016, Current medicinal chemistry.

[35]  N. Nalivaeva,et al.  AChE and the amyloid precursor protein (APP) - Cross-talk in Alzheimer's disease. , 2016, Chemico-biological interactions.

[36]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[37]  Yuqiong Pei,et al.  Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors , 2016, PeerJ.

[38]  V. Andrisano,et al.  Novel 8‐Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer′s Disease , 2016, ChemMedChem.

[39]  Keith F. Tipton,et al.  Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease , 2016, Front. Neurosci..

[40]  S. Lewis,et al.  Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia , 2016, Current neuropharmacology.

[41]  Xia Zhang,et al.  Role of oxidative stress in Alzheimer's disease , 2016, Biomedical reports.

[42]  Oliver Wirths,et al.  Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease , 2014, Acta Neuropathologica.

[43]  C. G. Mohan,et al.  Chemical Modifications of Cinchona Alkaloids Lead to Enhanced Inhibition of Human Butyrylcholinesterase , 2014, Natural product communications.

[44]  Sai-Sai Xie,et al.  Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. , 2013, European journal of medicinal chemistry.

[45]  Ashley I. Bush,et al.  Metal dyshomeostasis and oxidative stress in Alzheimer’s disease , 2013, Neurochemistry International.

[46]  Z. Kovarik,et al.  Peripheral site and acyl pocket define selective inhibition of mouse butyrylcholinesterase by two biscarbamates. , 2013, Archives of biochemistry and biophysics.

[47]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.

[48]  N. Inestrosa,et al.  Interactions of AChE with Aβ Aggregates in Alzheimer’s Brain: Therapeutic Relevance of IDN 5706 , 2011, Front. Mol. Neurosci..

[49]  A. Contestabile.  The history of the cholinergic hypothesis , 2011, Behavioural Brain Research.

[50]  L. Wessjohann,et al.  Cation-π and π-π stacking interactions allow selective inhibition of butyrylcholinesterase by modified quinine and cinchonidine alkaloids. , 2011, Biochemical and biophysical research communications.

[51]  H. Kozłowski,et al.  Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation) , 2009 .

[52]  A. Rauk.  The chemistry of Alzheimer's disease. , 2009, Chemical Society reviews.

[53]  Lisa Yan,et al.  Fully Automated Molecular Mechanics Based Induced Fit Protein-Ligand Docking Method , 2008, J. Chem. Inf. Model..

[54]  Hualiang Jiang,et al.  Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. , 2008, Biophysical journal.

[55]  A. Korczyn.  The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[56]  Z. Kovarik,et al.  Amino acid residues involved in stereoselective inhibition of cholinesterases with bambuterol. , 2008, Archives of biochemistry and biophysics.

[57]  N. Inestrosa,et al.  Amyloid–cholinesterase interactions , 2008, The FEBS journal.

[58]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[59]  Maurizio Recanatini,et al.  Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. , 2007, Journal of medicinal chemistry.

[60]  Yuan-Ping Pang,et al.  Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. , 2006, Journal of medicinal chemistry.

[61]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[62]  A. Field,et al.  Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. , 2005, Rheumatology.

[63]  I. Primožič,et al.  Enantiomers of quinuclidin-3-ol derivatives: resolution and interactions with human cholinesterases , 2005 .

[64]  A. A. Starkov,et al.  Mitochondrial metabolism of reactive oxygen species , 2005, Biochemistry (Moscow).

[65]  Subhash D. Katewa,et al.  Antimalarials Inhibit Human Erythrocyte Membrane Acetylcholinesterase , 2005, Drug and chemical toxicology.

[66]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[67]  Ashley I. Bush,et al.  The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.

[68]  Franz Worek,et al.  Molar absorption coefficients for the reduced Ellman reagent: reassessment. , 2003, Analytical biochemistry.

[69]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[70]  William J Egan,et al.  Prediction of intestinal permeability. , 2002, Advanced drug delivery reviews.

[71]  M. Mesulam,et al.  Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.

[72]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[73]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[74]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[75]  R. Dulbecco,et al.  PLAQUE FORMATION AND ISOLATION OF PURE LINES WITH POLIOMYELITIS VIRUSES , 1954, The Journal of experimental medicine.

[76]  L. Baum,et al.  Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. , 2004, Journal of Alzheimer's disease : JAD.

[77]  Z. Kovarik,et al.  Exploring the active sites of cholinesterases by inhibition with bambuterol and haloxon , 2003 .

[78]  E. Reiner,et al.  Inhibition of Human Blood Acetylcholinesterase and Butyrylcholinesterase by Ethopropazine , 2001 .

[79]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.